Company / Free Cash Flow per Share
NeoGenomics Laboratories, Inc. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$0.17
FY2025
5-year range
-$0.78 / -$0.17
FY2021-FY2025
Trend
+36.7%
vs FY2024
Sector context
#124 of 148
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s free cash flow per share of $-0.17 is lower than 84% of companies in the Health Care sector (FY2025). Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-0.78 in FY2022 to $0.33 in FY2018.
Based on SEC 10-K filings.
-0.17 in FY2025.
Improved from $-0.24 to $-0.17 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 148This company -$0.17 Sector average $5.04
▼
-103.4% below sector average
Key checks
Key Insights
- In FY2025, free cash flow per share increased 36.7% year-over-year.
- Ranks #124 out of 148 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2018.
- Lowest free cash flow per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.17 | +36.7% |
| FY2024 | -$0.27 | -9.8% |
| FY2023 | -$0.24 | +68.6% |
| FY2022 | -$0.78 | -3.0% |
| FY2021 | -$0.76 | -206.4% |
| FY2020 | -$0.25 | -866.9% |
| FY2019 | $0.03 | -90.3% |
| FY2018 | $0.33 | +501.6% |
| FY2017 | $0.06 | -69.9% |
| FY2016 | $0.18 | +165.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026